286 related articles for article (PubMed ID: 26711563)
21. Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67).
Guasp M; Solà-Valls N; Martínez-Hernández E; Gil MP; González C; Brieva L; Saiz A; Dalmau J; Graus F; Ariño H
J Neuroimmunol; 2016 Nov; 300():15-17. PubMed ID: 27806870
[TBL] [Abstract][Full Text] [Related]
22. [Proposal of a diagnostic algorithm for autoimmune epilepsy: preliminary investigation of its utility].
Sakamoto M; Matsumoto R; Togawa J; Hashi Y; Takeyama H; Kobayashi K; Shimotake A; Kondo T; Takahashi R; Ikeda A
Rinsho Shinkeigaku; 2018 Oct; 58(10):609-616. PubMed ID: 30270338
[TBL] [Abstract][Full Text] [Related]
23. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment.
Muñoz-Lopetegi A; de Bruijn MAAM; Boukhrissi S; Bastiaansen AEM; Nagtzaam MMP; Hulsenboom ESP; Boon AJW; Neuteboom RF; de Vries JM; Sillevis Smitt PAE; Schreurs MWJ; Titulaer MJ
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32123047
[TBL] [Abstract][Full Text] [Related]
24. Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications.
Lilleker JB; Biswas V; Mohanraj R
Seizure; 2014 Sep; 23(8):598-602. PubMed ID: 24836709
[TBL] [Abstract][Full Text] [Related]
25. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis.
Malter MP; Helmstaedter C; Urbach H; Vincent A; Bien CG
Ann Neurol; 2010 Apr; 67(4):470-8. PubMed ID: 20437582
[TBL] [Abstract][Full Text] [Related]
26. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders.
Fouka P; Alexopoulos H; Akrivou S; Trohatou O; Politis PK; Dalakas MC
J Neuroimmunol; 2015 Apr; 281():73-7. PubMed ID: 25867471
[TBL] [Abstract][Full Text] [Related]
27. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics of GAD 65-associated autoimmune encephalitis.
Zhu F; Shan W; Lv R; Li Z; Wang Q
Acta Neurol Scand; 2020 Sep; 142(3):281-293. PubMed ID: 32416610
[TBL] [Abstract][Full Text] [Related]
29. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase.
Markakis I; Alexiou E; Xifaras M; Gekas G; Rombos A
Clin Neurol Neurosurg; 2008 Jun; 110(6):619-21. PubMed ID: 18433986
[TBL] [Abstract][Full Text] [Related]
30. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.
Honnorat J; Saiz A; Giometto B; Vincent A; Brieva L; de Andres C; Maestre J; Fabien N; Vighetto A; Casamitjana R; Thivolet C; Tavolato B; Antoine J; Trouillas P; Graus F
Arch Neurol; 2001 Feb; 58(2):225-30. PubMed ID: 11176960
[TBL] [Abstract][Full Text] [Related]
31. Glutamic acid decarboxylase autoantibodies and neurological disorders.
Vianello M; Tavolato B; Giometto B
Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
[TBL] [Abstract][Full Text] [Related]
32. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases.
Manto MU; Laute MA; Aguera M; Rogemond V; Pandolfo M; Honnorat J
Ann Neurol; 2007 Jun; 61(6):544-51. PubMed ID: 17600364
[TBL] [Abstract][Full Text] [Related]
33. [Clinical characteristics of four patients with temporal lobe epilepsy associated with elevated anti-GAD antibodies].
Akaishi T; Jin K; Kato K; Itabashi H; Misu T; Tateyama M; Iwasaki M; Aoki M; Nakasato N
Rinsho Shinkeigaku; 2015; 55(11):804-9. PubMed ID: 26369378
[TBL] [Abstract][Full Text] [Related]
34. [Anti-GAD antibodies in paraneoplastic cerebellar ataxia associated with limbic encephalitis and autonomic dysfunction].
Carra-Dalliere C; Thouvenot E; Bonafé A; Ducray F; Touchon J; Charif M
Rev Neurol (Paris); 2012 Apr; 168(4):363-6. PubMed ID: 22405456
[TBL] [Abstract][Full Text] [Related]
35. Limbic encephalitis associated with glutamic acid decarboxylase antibodies in a young adolescent.
M'zahem A; Meziani A; Taghane N; Boulefkhad A; Khellaf S; Hamri A
Rev Neurol (Paris); 2016; 172(4-5):327-8. PubMed ID: 27117742
[No Abstract] [Full Text] [Related]
36. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders.
Chengyu L; Weixiong S; Chao C; Songyan L; Lin S; Zhong Z; Hua P; Fan J; Na C; Tao C; Jianwei W; Haitao R; Hongzhi G; Xiaoqiu S
J Neuroimmunol; 2020 Aug; 345():577289. PubMed ID: 32563127
[TBL] [Abstract][Full Text] [Related]
37. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
38. Stiff Person syndrome and other anti-GAD-associated neurologic disorders.
Dayalu P; Teener JW
Semin Neurol; 2012 Nov; 32(5):544-9. PubMed ID: 23677666
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune encephalitis associated with glutamic acid decarboxylase antibodies: a case series.
Incecik F; Herguner OM; Besen S; Yılmaz M
Acta Neurol Belg; 2018 Sep; 118(3):411-414. PubMed ID: 29349679
[TBL] [Abstract][Full Text] [Related]
40. Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome.
Jarius S; Stich O; Speck J; Rasiah Ch; Wildemann B; Meinck HM; Rauer S
J Neuroimmunol; 2010 Dec; 229(1-2):219-24. PubMed ID: 20813415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
